EPAM Systems (EPAM) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
13 Dec, 2025Executive summary
Q4 2024 revenues reached $1.25 billion, up 7.9% year-over-year, with full-year revenues at $4.73 billion, reflecting a 5-year CAGR of 16%.
Non-GAAP diluted EPS for Q4 was $2.84, up 3.3% year-over-year; GAAP diluted EPS was $1.80, up 8.4%.
Recent acquisitions of Neoris and First Derivative expanded global footprint, client relationships, and capabilities in Latin America and financial services.
Recognized for leadership in AI, digital platform engineering, and as a top workplace by multiple industry sources.
Operates in 55+ countries, serving 340+ Forbes Global 2000 clients across 11 industries.
Financial highlights
Q4 2024 revenue was $1.25 billion, up 7.9% year-over-year (1% organic constant currency growth); full-year revenue was $4.73 billion, up 0.8%.
Q4 GAAP income from operations was $137 million (10.9% of revenue); non-GAAP income from operations was $208 million (16.7% of revenue).
Full-year GAAP income from operations was $545 million (11.5% of revenue); non-GAAP was $779 million (16.5% of revenue).
Q4 cash flow from operations was $130 million; full-year cash flow from operations was $559 million.
Ended Q4 with $1.3 billion in cash and equivalents, down due to acquisitions.
Outlook and guidance
2025 revenue growth expected at 10%-14%, with inorganic contribution of ~10% and negative FX impact of 0.9%.
2025 GAAP income from operations expected at 9%-10%; non-GAAP at 14.5%-15.5%.
2025 GAAP EPS guidance: $6.78-$7.08; non-GAAP EPS: $10.45-$10.75.
Q1 2025 revenue guidance: $1.275-$1.290 billion (approx. 10% growth, 11.4% inorganic); Q1 GAAP operating margin: 6.5%-7.5%.
Profitability expected to improve in the second half of 2025 as investments in talent and GenAI platforms continue.
Latest events from EPAM Systems
- Accelerating as an AI-native leader, targeting 16%+ margins and $1.8B+ free cash flow by 2028.EPAM
Investor Day 202612 Mar 2026 - Strong 2025 growth and AI momentum support a robust 2026 outlook for revenue and EPS.EPAM
Q4 202519 Feb 2026 - Q2 revenue down 2% YoY; healthcare strong, margins lower, new $500M buyback approved.EPAM
Q2 20242 Feb 2026 - Q3 revenue and EPS rose, NEORIS acquisition expanded reach, and share buybacks accelerated.EPAM
Q3 202416 Jan 2026 - Board declassification, majority voting, and new incentive plan headline 2025 proxy.EPAM
Proxy Filing1 Dec 2025 - Proxy seeks approval for board declassification, majority voting, and new long-term incentive plan.EPAM
Proxy Filing1 Dec 2025 - Key votes include director elections, governance reforms, and executive pay approval.EPAM
Proxy Filing1 Dec 2025 - Leadership transition announced: Dobkin to Executive Chairman, Fejes to CEO in September 2025.EPAM
Proxy Filing1 Dec 2025 - Q2 revenue up 18% year-over-year; full-year outlook raised, margins pressured by higher costs.EPAM
Q2 202523 Nov 2025